Reviewing the landscape of COVID-19 therapeutics shows how uneven the evidence remains across drug classes. Remdesivir delivered mixed results—some trials showed faster recovery, but large international data suggested little overall benefit, leading to differing guideline positions. Corticosteroids remain one of the few consistently supported treatments, especially for patients requiring oxygen. Monoclonal antibodies offer benefit in early, high-risk outpatient cases but not in hospitalized settings. Meanwhile, drugs like lopinavir/ritonavir, hydroxychloroquine, and convalescent plasma have repeatedly failed to show meaningful clinical impact. Evidence around agents such as ivermectin, MSCs, favipiravir, molnupiravir, and supplements remains thin or inconsistent, leaving major gaps and reinforcing the need for more reliable, targeted COVID-19 treatments.